By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Janssen Pharmaceutica, part of Johnson & Johnson's Janssen Pharmaceutical division, will develop assays on the Biocartis molecular diagnostics system, Biocartis said today.

Under the agreement, Janssen and J&J's Ortho-Clinical Diagnostics group will have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.